These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
26. Korean ginseng extract attenuates reserpine-induced orofacial dyskinesia and improves cognitive dysfunction in rats. Sanghavi CR; Barhate SA; Mahajan MS; Mohan M; Kasture SB Nat Prod Res; 2011 Apr; 25(7):704-15. PubMed ID: 20628966 [TBL] [Abstract][Full Text] [Related]
27. Relationship of orofacial movements to behavioural repertoire as assessed topographically over the course of 6-month haloperidol treatment followed by 4-month withdrawal. De Souza IE; Dawson NM; Clifford JJ; Waddington JL; Meredith GE Psychopharmacology (Berl); 2003 Aug; 169(1):28-34. PubMed ID: 12830366 [TBL] [Abstract][Full Text] [Related]
28. Involvement of adenosinergic receptor system in an animal model of tardive dyskinesia and associated behavioural, biochemical and neurochemical changes. Bishnoi M; Chopra K; Kulkarni SK Eur J Pharmacol; 2006 Dec; 552(1-3):55-66. PubMed ID: 17064683 [TBL] [Abstract][Full Text] [Related]
29. Effects of buspirone on an animal model of tardive dyskinesia. Queiroz CM; Frussa-Filho R Prog Neuropsychopharmacol Biol Psychiatry; 1999 Nov; 23(8):1405-18. PubMed ID: 10631766 [TBL] [Abstract][Full Text] [Related]
31. Reversal of haloperidol-induced tardive vacuous chewing movements and supersensitive somatodendritic serotonergic response by buspirone in rats. Haleem DJ; Samad N; Haleem MA Pharmacol Biochem Behav; 2007 May; 87(1):115-21. PubMed ID: 17498786 [TBL] [Abstract][Full Text] [Related]
32. Repeated resveratrol administration confers lasting protection against neuronal damage but induces dose-related alterations of behavioral impairments after global ischemia. Girbovan C; Morin L; Plamondon H Behav Pharmacol; 2012 Feb; 23(1):1-13. PubMed ID: 22146698 [TBL] [Abstract][Full Text] [Related]
33. Possible anti-oxidant and neuroprotective mechanisms of zolpidem in attenuating typical anti-psychotic-induced orofacial dyskinesia: a biochemical and neurochemical study. Bishnoi M; Chopra K; Kulkarni SK Prog Neuropsychopharmacol Biol Psychiatry; 2007 Jun; 31(5):1130-8. PubMed ID: 17513028 [TBL] [Abstract][Full Text] [Related]
34. Reversal of haloperidol-induced orofacial dyskinesia by Murraya koenigii leaves in experimental animals. Patil R; Hiray Y; Shinde S; Langade P Pharm Biol; 2012 Jun; 50(6):691-7. PubMed ID: 22136413 [TBL] [Abstract][Full Text] [Related]
35. Reserpine does not induce orofacial dyskinesia in spontaneously hypertensive rats. Queiroz CM; Piovezan RD; Frussa-Filho R Eur J Pharmacol; 1998 Sep; 356(2-3):105-8. PubMed ID: 9774239 [TBL] [Abstract][Full Text] [Related]
36. Bauhinia forficata prevents vacuous chewing movements induced by haloperidol in rats and has antioxidant potential in vitro. Peroza LR; Busanello A; Leal CQ; Röpke J; Boligon AA; Meinerz D; Libardoni M; Athayde ML; Fachinetto R Neurochem Res; 2013 Apr; 38(4):789-96. PubMed ID: 23377855 [TBL] [Abstract][Full Text] [Related]
37. Parallels between behavioral and neurochemical variability in the rat vacuous chewing movement model of tardive dyskinesia. Bachus SE; Yang E; McCloskey SS; Minton JN Behav Brain Res; 2012 Jun; 231(2):323-36. PubMed ID: 22503783 [TBL] [Abstract][Full Text] [Related]
38. Haloperidol-induced extra pyramidal symptoms attenuated by imipramine in rats. Samad N; Haleem DJ Pak J Pharm Sci; 2014 Sep; 27(5 Spec no):1497-501. PubMed ID: 25176243 [TBL] [Abstract][Full Text] [Related]